Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05535738 · ClinicalTrials.gov registry record · Phase 2
Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation
A Phase 2 study of Skin Inflammation and Allergic Contact Dermatitis, sponsored by Wei-Che Ko.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT05535738: Recruiting Phase 2 study of Skin Inflammation and Allergic Contact Dermatitis, sponsored by Wei-Che Ko.
NCT05535738 is a Phase 2 study of Skin Inflammation and Allergic Contact Dermatitis that is actively recruiting participants, run by Wei-Che Ko. The registered enrollment target is 45 participants, above the 41-participant average among 4 other Skin Inflammation trials with a reported enrollment target (10% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05535738, a Phase 2 study of Skin Inflammation and Allergic Contact Dermatitis, is actively recruiting participants, sponsored by Wei-Che Ko.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to answer: how do inflammation and anti-inflammatory skin therapies work in the skin? Inflammation is a protective response from the body's immune system to injury, disease, or irritation. It is a process by which your body's white blood cells and the things they make protect you from infection from outside invaders such as bacteria and viruses.
Primary Outcome
Baseline and after pre-treatment with immunomodulating medication
Conditions Studied
Interventions
- DRUG Ustekinumab
- DRUG Dupilumab
- DRUG Squaric Acid Dibutyl Ester
- OTHER Known patch test allergens
- DRUG Adalimumab
Study Locations (1)
Massachusetts
- University of Massachusetts Chan Medical School - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2022-11-15 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
What NCT05535738 shows while recruiting
NCT05535738 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, above the 41-participant average among 4 other Skin Inflammation trials with a reported enrollment target (10% higher).
The record links to 2 conditions, with Skin Inflammation appearing as the primary indexed condition, and to 5 interventions - of which Ustekinumab is the first listed.
NCT05535738 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05535738 about?
NCT05535738 is a clinical study titled "Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation". The purpose of this study is to answer: how do inflammation and anti-inflammatory skin therapies work in the skin? Inflammation is a protective response from the body's immune system to injury, disease, or irritation. It is a process by which your body's white blood cells and the things they make pr...
What is the current status of trial NCT05535738?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2022-11-15. Estimated completion is 2027-12-31.
What conditions does trial NCT05535738 study?
This clinical trial studies the following conditions: Skin Inflammation, Allergic Contact Dermatitis.
What interventions are being tested in trial NCT05535738?
The interventions under investigation include: Ustekinumab (DRUG), Dupilumab (DRUG), Squaric Acid Dibutyl Ester (DRUG), Known patch test allergens (OTHER), Adalimumab (DRUG).
Who is sponsoring clinical trial NCT05535738?
This trial is sponsored by Wei-Che Ko, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05535738 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI